Communiqués Evogene Ltd.

Actions

EVGN

IL0011050551

Recherche biotechnologique et médicale

Temps Différé TEL AVIV STOCK EXCHANGE Autres places de cotation 15:13:11 10/08/2026			Varia. 5j.	Varia. 1 janv.
220,00 ^ILa	+8,70%		+51,52%	-26,81%

27/07	L.I.A. Pure Capital Ltd adresse un courriel à Evogene Ltd	CI
22/07	Evogene Ltd. et Eleo Inc. annoncent une collaboration pour le développement d'inhibiteurs oraux de la voie PCSK9 de nouvelle génération contre l'hyperlipidémie et les maladies cardiovasculaires	CI

Communiqués

30/07	Evogene Schedules Second Quarter 2026 Financial Results Release	PR
22/07	Evogene Ltd. and ELEO Inc. Announce Collaboration to Develop Next-Generation Oral Small-Molecule PCSK9 Pathway Inhibitors for Hyperlipidemia and Cardiovascular Diseases	PR
08/07	Evogene : and Tel Aviv University’s Blavatnik Center for Drug Discovery Announce Joint Initiative to Accelerate AI-Driven Small-Molecule Drug Discovery	PU
02/06	Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica	PR
20/05	Evogene : Q1 2026 Consolidated Financial Statements	PU
20/05	Evogene: Q1 Earnings Snapshot	AQ
20/05	Evogene Reports First Quarter 2026 Financial Results	PR
12/05	Evogene to Present at the 24th Schrödinger European User Group Meeting	PR
07/05	Evogene Schedules First Quarter 2026 Financial Results Release	PR
02/04	Evogene Reports Receipt of Nasdaq Minimum Bid Price Notification	PR
31/03	Casterra Announces Successful Commercial Field Trials in Brazil, Positioning Castor Oil as a Promising Candidate for Economically Viable Biofuel Feedstock	PR
05/03	Evogene : Q4 and Full Year 2025 Consolidated Financial Statements	PU
05/03	Evogene: Q4 Earnings Snapshot	AQ
05/03	Evogene Reports Fourth Quarter and Full Year 2025 Financial Results	PR
25/02	Evogene Releases CEO Letter to Shareholders	PR
17/02	Evogene and Queensland University of Technology (QUT) Announce a Collaboration to Advance AI-Driven Cancer Therapeutics	PR
11/02	Evogene, Systasy and LMU University Hospital Munich Announce a Collaboration to Develop Novel Therapies for Neutrophil-Derived Inflammatory Diseases	PR
10/02	Evogene Announces a Warrant Inducement Transaction for Approximately $3.4 Million of Gross Proceeds	PR
05/02	Evogene and Shanghai Lishan Biopharmaceuticals Co. Announce Exclusive Licensing Agreement for BMC128, a Microbiome-Based Therapeutic for Renal and Lung Cancer	AQ
07/01	Evogene and Unravel Biosciences Announce Collaboration to Develop a First-in-Class Therapy to Reverse Neurological Damage in Demyelinating Disorders	PR
31/12	Evogene Announces Appointment of Dr. Olga Nissan as its Vice President of Business Development	AQ
27/11	Evogene : Presentation	PU
20/11	Evogene : Q3 2025 Consolidated Financial Statements	PU
20/11	Evogene Reports Third Quarter 2025 Financial Results	PR
20/11	Evogene: Q3 Earnings Snapshot	AQ